TG Therapeutics Inc. (TGTX) Earns Buy Rating from Ladenburg Thalmann
TG Therapeutics Inc. (NASDAQ:TGTX)‘s stock had its “buy” rating restated by Ladenburg Thalmann in a research report issued on Saturday. They currently have a $28.00 target price on the biopharmaceutical company’s stock. Ladenburg Thalmann’s target price indicates a potential upside of 324.89% from the stock’s current price.
TGTX has been the topic of a number of other reports. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a report on Monday, September 19th. S&P Equity Research cut their price target on TG Therapeutics from $7.15 to $6.40 in a report on Wednesday, August 24th. Brean Capital restated a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a report on Thursday, October 6th. Roth Capital restated a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a report on Wednesday, August 10th. Finally, Zacks Investment Research cut TG Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, July 14th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the stock. TG Therapeutics presently has an average rating of “Buy” and a consensus target price of $21.21.
TG Therapeutics (NASDAQ:TGTX) traded down 3.80% during trading on Friday, hitting $6.59. 1,109,795 shares of the company traded hands. The stock has a 50-day moving average price of $7.39 and a 200-day moving average price of $7.37. The firm’s market capitalization is $358.87 million. TG Therapeutics has a 12-month low of $5.41 and a 12-month high of $14.87.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.29) by $0.04. TG Therapeutics had a negative return on equity of 58.77% and a negative net margin of 40,142.11%. Equities analysts expect that TG Therapeutics will post ($1.22) EPS for the current fiscal year.
A number of large investors have recently added to or reduced their stakes in TGTX. UBS Asset Management Americas Inc. raised its stake in TG Therapeutics by 30.0% in the first quarter. UBS Asset Management Americas Inc. now owns 2,021,310 shares of the biopharmaceutical company’s stock worth $17,223,000 after buying an additional 466,193 shares during the last quarter. Mariner Wealth Advisors LLC raised its stake in TG Therapeutics by 1.4% in the first quarter. Mariner Wealth Advisors LLC now owns 18,286 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 255 shares during the last quarter. Bridger Management LLC bought a new stake in TG Therapeutics during the first quarter worth approximately $28,503,000. Opaleye Management Inc. raised its stake in TG Therapeutics by 38.3% in the first quarter. Opaleye Management Inc. now owns 415,000 shares of the biopharmaceutical company’s stock worth $3,536,000 after buying an additional 115,000 shares during the last quarter. Finally, Bank of New York Mellon Corp raised its stake in TG Therapeutics by 8.4% in the second quarter. Bank of New York Mellon Corp now owns 176,637 shares of the biopharmaceutical company’s stock worth $1,070,000 after buying an additional 13,749 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.